Is Immunome Inc. (IMNM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 9.4% / 30% | 0.0% / 30% | 141.99% / 5% | ✗ NOT HALAL |
| DJIM | 0.2% / 33% | 9.4% / 33% | 0.0% / 33% | 141.99% / 5% | ✗ NOT HALAL |
| MSCI | 2.0% / 33% | 90.5% / 33% | 0.0% / 33% | 141.99% / 5% | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 9.4% / 33% | 0.0% / 33% | 141.99% / 5% | ✗ NOT HALAL |
| FTSE | 2.0% / 33% | 90.5% / 33% | 0.0% / 50% | 141.99% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -3084.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -52.1% | |
| Return on Assets (ROA) | -29.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$191M |
| Free Cash Flow | -$207M |
| Total Debt | $4M |
| Debt-to-Equity | 0.6 |
| Current Ratio | 14.7 |
| Total Assets | $683M |
Price & Trading
| Last Close | $20.41 |
| 50-Day MA | $22.66 |
| 200-Day MA | $15.97 |
| Avg Volume | 1.6M |
| Beta | 2.2 |
|
52-Week Range
$5.15
| |
About Immunome Inc. (IMNM)
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Immunome Inc. (IMNM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Immunome Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Immunome Inc.'s debt ratio?
Immunome Inc.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.0%.
What are Immunome Inc.'s key financial metrics?
Immunome Inc. has a market capitalization of $2.2B, and revenue of $7M. Return on equity stands at -52.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.